Hoya Vision Care revealed the findings from an 8-year follow-up clinical study evaluating the long-term effects of myopia control and user experience for patients using Defocus Incorporated Multiple Segments (DIMS) spectacle lenses. The announcement, made during the International Myopia Conference (IMC) in Sanya, China, marks the completion of the longest-running study on MiYOSMART myopia management lenses conducted globally.

The study monitored a group of participants who had initially taken part in the original 2-year randomized controlled trial (RCT) of DIMS lenses. A significant portion of these participants, 60%, continued wearing the DIMS spectacle lenses for as long as 8 years. Results indicated that all participants were satisfied with the benefits of the lenses, which also increased their awareness of myopia management, according to Hoya.

“With myopia on the rise, it is important for eye care professionals to choose treatments to slow the progression in children based on best evidence available. Previous research has shown that the DIMS Spectacle Lenses appear to be a safe and effective method for managing myopia among the study population," Professor Carly Lam, the principal investigator of the study, said in a company news release. "We’re looking forward to seeing the impact of longer-term use on myopia management in this pediatric population.”

The DIMS lenses, which form the foundation of Hoya's MiYOSMART technology, use defocus theory to counteract myopia progression. This noninvasive technology corrects vision on the entire surface of the lens while incorporating a ring-shaped treatment area that works to slow down myopia progression. This alternation of focus and defocus areas is designed to enable clear vision and simultaneous myopia control.